Data Sheet (Cat.No.T63674)

TargetMol

Imlunestrant

Chemical Properties



CAS No. : 2408840-26-4

Formula: C29H24F4N2O3

Molecular Weight: 524.51

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Imlunestrant (LY-3484356) is an orally active, selective estrogen receptor degrader that persistently inhibits ER-dependent gene transcription and cell growth. It is suitable for investigating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Targets(IC50)	Estrogen Receptor/ERR
In vitro	Imlunestrant exhibits favorable pharmacokinetic (PK) properties, including antitumor activity in ESR1 mutants [1].

Solubility Information

Solubility	DMSO: 140 mg/mL (266.92 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9065 mL	9.5327 mL	19.0654 mL
5 mM	0.3813 mL	1.9065 mL	3.8131 mL
10 mM	0.1907 mL	0.9533 mL	1.9065 mL
50 mM	0.0381 mL	0.1907 mL	0.3813 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. 2021 ASCO Annual Meeting I.

Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22(15), 7812.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481